

#1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_

**Menactra, Menveo, ACWJ, MenB Series \_\_\_ SIGN ENCLOSED MENINGITIS RESPONSE FORM**

#1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_ #3 \_\_\_/\_\_\_/\_\_\_ **Tunenba or Bexero**

:  
Moderna #1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_  
Pfizer #1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_  
Johnson & Johnson (Janssen) #1 \_\_\_/\_\_\_/\_\_\_

\_\_\_ I wish to apply for vaccine exemption (See Le Moyne Health Services Webpage)

**VACCINE DATE** \_\_\_/\_\_\_/\_\_\_  
\_\_\_/\_\_\_/\_\_\_ **VACCINE NAME** \_\_\_\_\_

**VACCINE DATES** #1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_

: **VACCINE DATES** #1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_ #3 \_\_\_/\_\_\_/\_\_\_

**(ADULT) BOOSTER DATE** \_\_\_/\_\_\_/\_\_\_ **(WITHIN THE PAST 10 YEARS)**

#1 \_\_\_/\_\_\_/\_\_\_ #2 \_\_\_/\_\_\_/\_\_\_ #3 \_\_\_/\_\_\_/\_\_\_

**1 Does the student have signs or symptoms of active tuberculosis disease? Yes \_\_\_ No \_\_\_**

**If Yes, proceed with additional evaluation to exclude active TB including Tuberculin skin testing chest X-ray and sputum evaluation as indicated**

**2 Is the student a member of a Yes \_\_\_ No \_\_\_**

**A history of BCG vaccination does not preclude testing of a high risk member:**

**Tuberculin Skin Test (Mantoux or TST) within past year**

**Date given \_\_\_ Date read \_\_\_ Result (in actual mm induration) \_\_\_**

**BCG manufacturer, lot # and expiration date \_\_\_\_\_**

**3 Chest X-ray (required if tuberculin test is positive)**

**Results Normal \_\_\_ Abnormal \_\_\_ Treatment: \_\_\_\_\_**

Categories of students include those students who have arrived in the past 5 years from countries where TB is endemic. It is easier to identify countries of rather than high TB prevalence. Therefore, students should undergo TB screening if they have arrived from countries those on the following list: Canada, Jamaica, St. Kitts and Nevis, Saint Lucia, Virgin Islands USA, Belgium, Denmark, Finland, France, Germany, Greece, Iceland/Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, San Marino, Sweden, Switzerland, United Kingdom, American Samoa, Australia, or New Zealand. Other categories of high risk congregate settings such as prisons, nursing homes, hospitals, residential facilities for patients with AIDS, or homeless shelters and those who have clinical conditions such as diabetes, chronic renal failure, leukemia, or lymphoma, low body weight, gastrectomy and jejunal bypass, chronic malabsorption syndromes, prolonged corticosteroid therapy (e.g. prednisone >15mg/day for >1 month) or other immunosuppressive disorders.

: \_\_\_\_\_ ( ) \_\_\_\_\_